CTOs on the Move

Taro Pharmaceuticals (HQ)

www.tarousa.com

 
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tarousa.com
  • 3 Skyline Dr Ste 120
    Hawthorne, NY USA 10532
  • Phone: 914.345.9001

Executives

Name Title Contact Details

Similar Companies

Cleveland Rape Crisis Center

Supporting survivors of sexual abuse and rape, promoting healing and prevention, and advocating for social change in Northeast Ohio

New York Cancer and Blood Specialists

New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.

Regulatory Affairs Professionals Society

RAPS is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.

Daiichi Sankyo

Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.